Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings
复制标题
DOI：
10.1007/s00520-006-0173-z
复制
发表时间：
2007-05-01
影响因子：
3.1
通讯作者：
Hu, Henry
中科院分区：
文献类型：
--
作者：
Cohen, Lorenzo;de Moor, Carl A.;Hu, Henry
工作目标：本研究旨在确定急性和迟发性化疗引起的恶心和呕吐（CINV）的患病率在10个社区肿瘤设置。同时评价CINV对生活质量的影响。材料与方法：从10个社区肿瘤诊所招募了计划进行新化疗方案第一周期的癌症患者。研究参与者通过在每个周期治疗后的前8天每天完成日记记录CINV的发生，并在化疗前、化疗后第1天和第6天结束时记录功能性生活指数-呕吐（FLIE）。采用混合模型回归分析探讨第1周期和后续周期CINV发生率之间的关系及其对患者生活质量的影响。主要结果：151例患者提供了至少一个周期的信息。在第1周期，只有33%既没有急性也没有迟发性CINV。在36%发生急性CINV的患者中，8%仅发生急性CINV。在发生迟发性CINV的59%患者中，53%仅报告迟发性CINV，47%报告急性和迟发性CINV。在第2和第3周期观察到类似的模式。第1周期CINV的经历与第2周期和第3周期CINV的发生相关。根据FLIE评估，CINV的发生显著干扰患者QOL。结论：在这个以社区为基础的样本中，CINV仍然是接受化疗的患者的一个重大问题，尤其是迟发性CINV。CINV显著干扰患者的生活质量和日常功能。
Goals of work: The present study sought to determine the prevalence of acute and delayed chemotherapy-induced nausea and vomiting (CINV) across ten community oncology settings. The effect of CINV on quality of life (QOL) was also evaluated. Materials and methods: Cancer patients who were scheduled for their first cycle of a new chemotherapy regimen were recruited from ten community oncology clinics. Study participants recorded occurrence of CINV by completing a daily diary each day for the first 8 days after treatment during each cycle and the Functional Living Index-Emesis (FLIE) before chemotherapy, at the end of day 1 and day 6 after chemotherapy. Mixed model regression analysis was used to explore the association between occurrence of CINV at cycle 1 and subsequent cycles and its impact on patient QOL. Main results: One hundred and fifty-one patients provided information for at least one cycle. During cycle 1, only 33% had neither acute nor delayed CINV. Of the 36% patients who developed acute CINV, 8% developed acute CINV only. Of the 59% who developed delayed CINV, 53% reported delayed only and 47% reported acute and delayed CINV. A similar pattern was seen at cycles 2 and 3. Experience of CINV at cycle 1 was associated with the development of CINV at cycles 2 and 3. Occurrence of CINV significantly interfered with patient QOL as assessed by the FLIE. Conclusions: CINV remained a substantial problem for patients receiving chemotherapy in this community-based sample, especially delayed CINV. CINV significantly interfered with patient QOL and daily functioning.